MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-12-2026
Eli Lilly and Company Depreciation & Amortization 2011-2026 | LLY
Annual Depreciation & Amortization Eli Lilly and Company
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2 B | 1.77 B | 1.53 B | 1.52 B | 1.55 B | 1.32 B | 1.23 B | 1.61 B | 1.57 B | 1.5 B | 1.43 B | 1.38 B | 1.45 B | 1.46 B | 1.37 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2 B | 1.23 B | 1.51 B |
Quarterly Depreciation & Amortization Eli Lilly and Company
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 463 M | - | - | 401 M | - | - | 362 M | - | 1.15 B | - | 436 M | - | 1.1 B | - | 350 M | - | 956 M | 598 M | 274 M | - | 892 M | 604 M | 356 M | - | 1.26 B | 848 M | 423 M | - | 1.16 B | 782 M | 387 M | - | 1.15 B | 759 M | 386 M | - | 1.08 B | 726 M | 358 M | - | 1.04 B | 697 M | 349 M | - | 1.09 B | 745 M | 382 M | - | 1.12 B | 748 M | 386 M | - | 1.05 B | 696 M | 341 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.26 B | 274 M | 700 M |
Depreciation & Amortization of other stocks in the Biotechnology industry
| Issuer | Depreciation & Amortization | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AbCellera Biologics
ABCL
|
18.4 M | $ 3.44 | -4.32 % | $ 1.03 B |  Canada |
 |
Acorda Therapeutics
ACOR
|
31.7 M | - | -24.86 % | $ 820 K |  USA |
 |
I-Mab
IMAB
|
23.9 M | - | - | $ 866 M |  China |
 |
Acer Therapeutics
ACER
|
66 K | - | 2.71 % | $ 14 M | USA |
 |
ADMA Biologics
ADMA
|
8 M | $ 15.36 | -2.17 % | $ 3.66 B | USA |
 |
AgeX Therapeutics
AGE
|
131 K | - | -10.17 % | $ 12.2 K | USA |
 |
Apellis Pharmaceuticals
APLS
|
1.56 M | $ 20.28 | 0.65 % | $ 2.56 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
744 K | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
1.51 M | - | - | $ 26.5 M | USA |
 |
Akero Therapeutics
AKRO
|
18 K | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
2.49 M | - | 0.23 % | $ 488 M | USA |
 |
Alpine Immune Sciences
ALPN
|
597 K | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
398 K | - | 4.14 % | $ 49.1 M | USA |
 |
Aptorum Group Limited
APM
|
1.13 M | $ 0.79 | -1.15 % | $ 4.31 M | China |
 |
Autolus Therapeutics plc
AUTL
|
7.55 M | $ 1.51 | 1.35 % | $ 385 M |  Britain |
 |
China SXT Pharmaceuticals
SXTC
|
82.3 K | $ 2.01 | -1.36 % | $ 2.86 M | China |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
42 K | $ 0.67 | 7.08 % | $ 624 K |  Israel |
 |
Adverum Biotechnologies
ADVM
|
3.65 M | - | - | $ 86.2 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
122 K | - | -11.43 % | $ 502 K | USA |
 |
Anika Therapeutics
ANIK
|
6.43 M | $ 14.05 | -1.44 % | $ 206 M | USA |
 |
ANI Pharmaceuticals
ANIP
|
67.7 M | $ 74.36 | -1.64 % | $ 1.44 B | USA |
 |
Aravive
ARAV
|
886 K | - | -13.39 % | $ 1.45 M | USA |
 |
ARCA biopharma
ABIO
|
27 K | - | 1052.0 % | $ 415 M | USA |
 |
Athersys
ATHX
|
1.43 M | - | 3.77 % | $ 22.4 M | USA |
 |
AVEO Pharmaceuticals
AVEO
|
67 K | - | - | $ 521 M | USA |
 |
Axsome Therapeutics
AXSM
|
503 K | $ 162.43 | 0.6 % | $ 8.08 B | USA |
 |
BioCryst Pharmaceuticals
BCRX
|
1.25 M | $ 8.49 | -0.18 % | $ 1.75 B | USA |
 |
BridgeBio Pharma
BBIO
|
5.43 M | $ 65.66 | -0.78 % | $ 12.6 B | USA |
 |
Acasti Pharma
ACST
|
7 K | - | 4.01 % | $ 150 M | Canada |
 |
Brainstorm Cell Therapeutics
BCLI
|
240 K | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
140 K | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
142 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Bellicum Pharmaceuticals
BLCM
|
11 K | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
9 M | - | -7.31 % | $ 87 M | USA |
 |
Aeterna Zentaris
AEZS
|
58 K | - | 5.93 % | $ 314 M | Canada |
 |
BioMarin Pharmaceutical
BMRN
|
79.6 M | $ 61.3 | 1.21 % | $ 11.8 B | USA |
 |
CymaBay Therapeutics
CBAY
|
681 K | - | - | $ 3.45 B | USA |